Analysed GENMAB A/S -SP ADR (GMAB:NASDAQ) News Sources
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14-04-2026
yahoo.com
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
13-04-2026
yahoo.com
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
01-04-2026
yahoo.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
27-03-2026
247wallst.com
Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts
26-03-2026
yahoo.com
What is the current price of GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The current price of GENMAB A/S -SP ADR (GMAB:NASDAQ) is $29.06.
GENMAB A/S -SP ADR (GMAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of GENMAB A/S -SP ADR (GMAB:NASDAQ) since the previous trading day is $0.86.
GENMAB A/S -SP ADR (GMAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of GENMAB A/S -SP ADR (GMAB:NASDAQ) since the previous trading day is 3.0496%.
What is the most recent average sentiment score for GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The most recent average sentiment score for GENMAB A/S -SP ADR (GMAB:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The most recent sentiment for GENMAB A/S -SP ADR (GMAB:NASDAQ) is .
SEC-8K** Filing Available For GENMAB A/S -SP ADR (GMAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.